ASYNTZEL
DEAD

Serial Number

97759562

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Jan 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ASYNTZEL Trademark

Serial Number: 97759562

ASYNTZEL is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on January 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

January 18, 2023

Registration Date

Not Registered

Published for Opposition

December 5, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 2, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 2, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 30, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 5, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 28, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 25, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 25, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 26, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jul 26, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jul 26, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 17, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 24, 2023 NWOS
NEW APPLICATION ENTERED
Jan 21, 2023 NWAP